Paclitaxel prodrug loaded high-density lipoprotein nanoparticles for chemoimmunotherapy of triple-negative breast cancer.

Saved in:
Bibliographic Details
Title: Paclitaxel prodrug loaded high-density lipoprotein nanoparticles for chemoimmunotherapy of triple-negative breast cancer.
Authors: Jiang LY; State Key Laboratory of Drug Research & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.; University of Chinese Academy of Sciences, Beijing, 100049, China., Zhu BY; State Key Laboratory of Drug Research & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.; University of Chinese Academy of Sciences, Beijing, 100049, China., Zhou LL; School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, 210023, China., Deng D; School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, 210023, China., Zhang XY; School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, 210023, China., Chen JM; State Key Laboratory of Drug Research & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.; University of Chinese Academy of Sciences, Beijing, 100049, China., Jiang PW; State Key Laboratory of Drug Research & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.; University of Chinese Academy of Sciences, Beijing, 100049, China., Wang GR; State Key Laboratory of Drug Research & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.; University of Chinese Academy of Sciences, Beijing, 100049, China., Yang QM; Qilu Pharmaceutical Co. Ltd., Jinan, 250100, China., Zhang MH; Qilu Pharmaceutical Co. Ltd., Jinan, 250100, China., Shan YQ; Qilu Pharmaceutical (Hainan) Co. Ltd., Haikou, 570314, China., Li HZ; Hongliang (Shanghai) Biopharmaceutical Technology Co. Ltd, Shanghai, 200131, China., Li YP; State Key Laboratory of Drug Research & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China. ypli@simm.ac.cn.; University of Chinese Academy of Sciences, Beijing, 100049, China. ypli@simm.ac.cn.; School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, 210023, China. ypli@simm.ac.cn.; Yantai Key Laboratory of Nanomedicine & Advanced Preparations, Yantai Institute of Pharmaceutical Science, Yantai, 264000, China. ypli@simm.ac.cn., Cai Y; State Key Laboratory of Drug Research & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China. s19-caiying@simm.ac.cn.; University of Chinese Academy of Sciences, Beijing, 100049, China. s19-caiying@simm.ac.cn.; Yantai Key Laboratory of Nanomedicine & Advanced Preparations, Yantai Institute of Pharmaceutical Science, Yantai, 264000, China. s19-caiying@simm.ac.cn.
Source: Acta pharmacologica Sinica [Acta Pharmacol Sin] 2026 Jun 11. Date of Electronic Publication: 2026 Jun 11.
Publication Type: Journal Article
Journal Info: Publisher: Nature Publishing Group Country of Publication: United States NLM ID: 100956087 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1745-7254 (Electronic) Linking ISSN: 16714083 NLM ISO Abbreviation: Acta Pharmacol Sin Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1745-7254
DOI:10.1038/s41401-026-01847-0